Asked by: Gregory Stafford (Conservative - Farnham and Bordon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help increase the uptake of generic and biosimilar medicines to meet the objectives set out in the Government’s Life Sciences Sector Plan.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The United Kingdom is a global leader in adopting biosimilar and generic medicines, which deliver major National Health Service savings and expand patient access to effective treatments sooner.
We are working with the Medicines and Healthcare products Regulatory Agency, the National Institute for Health and Care Excellence (NICE), and NHS England to understand forthcoming biosimilars and to ensure they reach the frontline efficiently. Through NHS England’s Best Value Biologicals Framework, clinicians start patients on the most cost‑effective biologics where appropriate, and switches are made swiftly and safely. This has already delivered £1.2 billion in savings over the past three years.
As set out in the 10‑Year Health Plan and Life Sciences Sector Plan, we are streamlining regulation, improving procurement, and reducing variation in uptake. NICE’s whole‑lifecycle approach ensures clinical pathways are regularly reviewed so that patients benefit as soon as cost‑effective generics and biosimilars become available, as seen in recent cancer treatments. These actions support timely access to effective off‑patent medicines and a sustainable, competitive market for the NHS.
Asked by: Gregory Stafford (Conservative - Farnham and Bordon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether the Government plans to reinstate the Life Sciences Council.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The United Kingdom’s world leading life sciences sector is central to our Industrial Strategy, driving growth, investment, and high-quality jobs. The sector is forecast to grow by £41 billion and create 100,000 jobs by 2030, supporting our ambition to lead Europe in life sciences by 2030.
The Life Sciences Council is an important forum that brings together senior industry and Government leaders to shape the sector’s future. The Government remains committed to this partnership and is looking to convene the council in due course.
Asked by: Gregory Stafford (Conservative - Farnham and Bordon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what consideration has been given to the role of the generic and biosimilar medicines sector in shaping life sciences policy, in the context of it supplying around 85% of NHS prescription drugs by volume.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The United Kingdom’s world leading life sciences sector is central to our Industrial Strategy, driving growth, investment, and high-quality jobs. As set out in the Life Sciences Sector Plan, which we developed while working closely with the sector, there is an opportunity for the National Health Service to save £1 billion over five years through biosimilars uptake, delivering value for patients and the NHS. The Life Sciences Council is an important forum that brings together senior industry and Government leaders to shape the sector’s future. The Government remains committed to this partnership and is looking to convene the council in due course.
Medicines UK and its members are represented on the Single National Formulary Industry Task and Finish Group. In addition, the Government is working to convene further task and finish groups to drive forward defined areas of the Life Sciences Sector Plan, including in the generic and biosimilars space. These groups will direct focused ministerial and official attention toward a clear set of priorities and will work closely with industry to deliver tangible progress within a set timeframe.
Asked by: Gregory Stafford (Conservative - Farnham and Bordon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of reinstating the Life Sciences Council with representation from the generic and biosimilar medicines industry.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The United Kingdom’s world leading life sciences sector is central to our Industrial Strategy, driving growth, investment, and high-quality jobs. As set out in the Life Sciences Sector Plan, which we developed while working closely with the sector, there is an opportunity for the National Health Service to save £1 billion over five years through biosimilars uptake, delivering value for patients and the NHS. The Life Sciences Council is an important forum that brings together senior industry and Government leaders to shape the sector’s future. The Government remains committed to this partnership and is looking to convene the council in due course.
Medicines UK and its members are represented on the Single National Formulary Industry Task and Finish Group. In addition, the Government is working to convene further task and finish groups to drive forward defined areas of the Life Sciences Sector Plan, including in the generic and biosimilars space. These groups will direct focused ministerial and official attention toward a clear set of priorities and will work closely with industry to deliver tangible progress within a set timeframe.
Asked by: Gregory Stafford (Conservative - Farnham and Bordon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, when the Government plans to establish a task and finish group to oversee delivery of the Life Sciences Sector Plan as it relates to generic and biosimilar medicines.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The United Kingdom’s world leading life sciences sector is central to our Industrial Strategy, driving growth, investment, and high-quality jobs. As set out in the Life Sciences Sector Plan, which we developed while working closely with the sector, there is an opportunity for the National Health Service to save £1 billion over five years through biosimilars uptake, delivering value for patients and the NHS. The Life Sciences Council is an important forum that brings together senior industry and Government leaders to shape the sector’s future. The Government remains committed to this partnership and is looking to convene the council in due course.
Medicines UK and its members are represented on the Single National Formulary Industry Task and Finish Group. In addition, the Government is working to convene further task and finish groups to drive forward defined areas of the Life Sciences Sector Plan, including in the generic and biosimilars space. These groups will direct focused ministerial and official attention toward a clear set of priorities and will work closely with industry to deliver tangible progress within a set timeframe.
Asked by: Gregory Stafford (Conservative - Farnham and Bordon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential impact of a respiratory modern service framework on winter pressures on the NHS.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
Modern service frameworks will define an aspirational, long-term outcome goal for a major condition and then identify the best evidenced interventions and the support for delivery. Early priorities will include cardiovascular disease, severe mental illness, and the first ever service framework for frailty and dementia.
The Government will consider other long-term conditions for future waves of modern service frameworks, including respiratory conditions. The criteria for determining other conditions for future modern service frameworks will be based on where there is potential for rapid and significant improvements in quality of care and productivity. There has not, therefore, been a specific assessment made in relation to winter pressures.
NHS England, working with the Department, the UK Health Security Agency, and other partners, is taking action to reduce the impact of respiratory conditions on the National Health Service this winter. Further details of the actions being taken to reduce demand on acute services during winter is available at the following link:
https://www.england.nhs.uk/long-read/urgent-and-emergency-care-plan-2025-26/
Asked by: Gregory Stafford (Conservative - Farnham and Bordon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what discussions he has had with stakeholders on his Department's modelling of workforce numbers in the 10 Year Workforce Plan.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Government will publish the 10 Year Workforce Plan in spring 2026. This plan will set out action to create a National Health Service workforce which is able to deliver the transformed service set out in the 10-Year Health Plan. It is important we do this in a robust and joined up way. We are therefore engaging extensively with partners to ensure this plan delivers for staff and patients.
That engagement began well before the call for evidence was closed. In early November, ministers hosted an event with nearly one hundred representatives of partner organisations to hear views from across the health system.
Engagement is now continuing while we analyse the submissions to our call for evidence, including a roundtable with medical royal colleges on 14 January, which I chaired.
We have committed to publishing regular workforce planning. This will start with the 10-Year Workforce Plan, which will include updated workforce modelling and its underlying assumptions when published in spring 2026. The updated workforce modelling will be subject to independent scrutiny by our appointed external scrutiny panel.
Asked by: Gregory Stafford (Conservative - Farnham and Bordon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he has made an assessment of the potential merits of extending business rates reimbursements to community pharmacies.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
In the 2025 Autumn Budget, the Government took the hard choices to protect the National Health Service in England and to continue to prioritise reducing waiting times. We have also stepped in to cap bills and help businesses, as part of a £4.3 billion support package.
This year, we have also increased funding to community pharmacies to almost £3.1 billion, the largest uplift in funding for any part of the NHS across 2024/25 and 2025/26.
The Department will consult Community Pharmacy England on any proposed changes to reimbursement and remuneration of pharmacy contractors for 2026/27 shortly.
Asked by: Gregory Stafford (Conservative - Farnham and Bordon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to prepare for potential flu outbreaks in winter 2025-26.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
We have done more than ever to prepare for winter this year with the development and better testing of winter plans. This includes surge capacity and escalation plans for urgent and emergency care.
The flu vaccination programme began on 1 September 2025 for children and pregnant women. Adults aged over 65 years old, those with long term health conditions, and frontline health and social care workers will start from 1 October 2025.
Further details of the plans for this year, including actions to reduce the effects of flu on demand for services, are set out in the Urgent and Emergency Care Plan for 2025/26, which is available at the following link:
https://www.england.nhs.uk/long-read/urgent-and-emergency-care-plan-2025-26/
On 16 September, the Secretary of State addressed a gathering of Chief Executives and undertook a joint visit with the NHS England Chief Executive to set out how winter preparations were being strengthened. A further meeting with Chief Executives on 3 November also focused on winter planning.
Asked by: Gregory Stafford (Conservative - Farnham and Bordon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department plans to introduce a modern service framework for kidney disease; and what steps he is taking to support early diagnosis and prevention.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
As announced in the 10-Year Health Plan, as well as an overall quality strategy, the National Quality Board is overseeing the development of a new series of service frameworks to accelerate progress in conditions where there is potential for rapid and significant improvements in quality of care and productivity.
Early priorities include cardiovascular disease, severe mental illness, and the first ever service framework for frailty and dementia. The Government will consider other long-term conditions with significant health and economic impacts for future waves of modern service frameworks.
NHS England is delivering a comprehensive programme to improve the diagnosis, treatment, and outcomes of people with kidney disease. In 2023, NHS England published a renal services transformation toolkit to support earlier identification of chronic kidney disease and strengthen management across the whole patient pathway.